Delphinus Medical Technologies
Delivering medical innovations to transform early detection of breast cancer and save women’s lives all over the world.
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | (33 %) | 81 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Delphinus Medical Technologies, Inc. is a pioneering company in the medical imaging sector, specializing in advanced breast ultrasound technology. The company has developed a unique 3D whole breast ultrasound system known as SoftVue, which incorporates a circular ultrasound transducer with triple acoustic detection. This technology provides comprehensive imaging by combining reflection imaging for tissue structure and transmission imaging to measure sound speed and attenuation, thereby presenting detailed tissue characteristics.
Delphinus primarily serves healthcare providers, including hospitals and diagnostic imaging centers, aiming to improve breast cancer risk assessment and screening processes. The company operates in the medical imaging market, which is characterized by rapid technological advancements and a growing demand for non-invasive diagnostic tools.
The business model of Delphinus revolves around the sale and leasing of its SoftVue systems, along with providing maintenance and support services. Revenue is generated through direct sales, long-term leasing agreements, and service contracts. The company also engages in collaborative research projects and clinical trials to further validate and enhance its technology, thereby expanding its market reach and credibility.
Keywords: breast ultrasound, 3D imaging, cancer risk assessment, medical imaging, SoftVue, healthcare providers, diagnostic technology, non-invasive screening, acoustic detection, clinical trials.